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http://dx.doi.org/10.1016/j.ccell.2014.10.015SUMMARYIncreasing chemotherapy delivery to tumors, while enhancing drug uptake and reducing side effects, is a
primary goal of cancer research. In mouse and human cancer models in vivo, we show that coadministration
of low-dose Cilengitide and Verapamil increases tumor angiogenesis, leakiness, blood flow, and Gemcita-
bine delivery. This approach reduces tumor growth, metastasis, and minimizes side effects while extending
survival. At a molecular level, this strategy alters Gemcitabine transporter and metabolizing enzyme expres-
sion levels, enhancing the potency of Gemcitabine within tumor cells in vivo and in vitro. Thus, the dual action
of low-dose Cilengitide, in vessels and tumor cells, improves chemotherapy efficacy. Overall, our data
demonstrate that vascular promotion therapy is a means to improve cancer treatment.INTRODUCTION
Enhancing chemotherapy delivery to tumors, improving tumor
growth control, reducing metastasis, and increasing survival
are all critical objectives of improved cancer therapy. Significant
efforts have focused on antiangiogenic strategies aimed at
reducing tumor blood vessel density to inhibit tumor growth.
Unfortunately, monotherapy with antiangiogenic agents has not
been as effective as hoped for (Okines and Cunningham,
2009). Despite improvements when used in combination with
chemotherapy, limitations still include (1) reduced chemotherapy
delivery, (2) enhanced tumor hypoxia, and (3) potentially elevated
tumormetastasis, at least in preclinical models (Ebos et al., 2009;Significance
Antiangiogenic agents have not produced widespread clinical
tumor hypoxia, antiangiogenic approaches reduce the chemo
Vascular normalization is a strategy to enhance the antitumor ef
dent and therefore difficult to implement clinically. Here we
vascular normalization strategies, that a radical approach of
and Verapamil, in combination with Gemcitabine, provides sub
previous dogma and indicate proof of principle that vascular
beyond standard therapy, thus opening a field of future resea
CPa`ez-Ribes et al., 2009). Attempts at increasing drug delivery by
improving blood flow in the tumor, while partially reducing tumor
vessel number, is an alternative strategy known as vascular
normalization (Carmeliet and Jain, 2011). Unfortunately, the tran-
sient nature of vascular normalization means that this approach
relies on a temporary window of opportunity for drug delivery
that may be difficult to predict and apply in the clinical setting
(Webb, 2005). Thus, the paradigms that underlie antiangiogenic
and vascular normalization strategies are still open for improve-
ment. Designing vascular modulation strategies that overcome
at least some of these issues is highly desirable.
Cilengitide, an avb3/avb5 integrin-specific RGD-mimetic
cyclic peptide, was developed originally as an antiangiogenicbenefits. By inhibiting cytotoxic drug delivery and elevating
therapy efficacy while increasing the tumor aggressiveness.
fects of chemotherapeutics, but this is time and dose depen-
establish, using methods distinct from antiangiogenic or
‘‘vascular promotion therapy,’’ using low-dose Cilengitide
stantial advantages for cancer therapy. Our data challenge
promotion could be a strategy to improve cancer therapy
rch.
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Figure 1. Combination ldCil, Ver, and Gem Reduces Tumor Growth while Enhancing Angiogenesis
(A) At 7 days postinoculation, LLC tumor-burdenedmice were treated, using a continuous treatment regime, with various combinations of 50 mg/kg ldCil, 5 mg/kg
Ver, Gem 75 mg/kg (Gem75), or Gem 200 mg/kg (Gem200) (n = 8–18 mice per group).
(legend continued on next page)
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Enhancing Chemotherapy Delivery and Efficacydrug (Nisato et al., 2003; Yamada et al., 2006). This drug also
showed some direct effects on promoting cancer cell death (Oli-
veira-Ferrer et al., 2008). Unfortunately, this drug has recently
been withdrawn from the CENTRIC phase III clinical trials for
the treatment of glioblastoma due to a lack of meeting primary
endpoints (http://meetinglibrary.asco.org/content/112780-132).
Thus, the opportunity to repurpose the use of this drug by ex-
ploiting its other properties becomes significant. We have shown
recently that low-dose Cilengitide (ldCil), in contrast to the higher
doses used in previous studies, can actually enhance tumor
angiogenesis, demonstrating that Cilengitide can have proan-
giogenic effects (Reynolds et al., 2009). Other studies using
the calcium channel blocker, Verapamil (Ver), have shown that
this drug can increase vessel dilation and blood flow, while
also having the ability to reduce the efflux of some commonly
used chemotherapeutics, such as Gemcitabine (Gem) (Bergman
et al., 2003; Kaelin et al., 1982).
Here we show that treatment combining low-dose Cilengitide
with Ver improves Gem efficacy. By enhancing tumor angio-
genesis and increasing the potency of Gem within tumor cells,
our data provide proof of principle that treatment involving
‘‘vascular promotion’’ provides an improved strategy for cancer
therapy.
RESULTS
Both non-small-cell lung cancer and pancreatic ductal adeno-
carcinoma (PDAC) have extremely poor prognoses. Although
first-line treatment of both diseases can include chemotherapy
with Gem, long-term survival rates are dire (Coate et al., 2009;
Hidalgo, 2010). We investigated whether combining ldCil and
Ver could enhance the efficacy of Gem in the treatment of lung
and pancreatic cancers.
Treatmentwith Combination ldCil, Ver, andGem Inhibits
Lung Cancer Growth while Increasing Tumor
Angiogenesis
C57/BL6 mice were injected subcutaneously with murine syn-
geneic Lewis lung carcinoma (LLC) cells. At 7 days postinocula-
tion, mice were treated continuously with either placebo, ldCil
(50 mg/kg) (Reynolds et al., 2009), Ver (5 mg/kg), Gem (at either
75 mg/kg [Gem75] or 200 mg/kg [Gem200]), or combinations of
the above. Tumor size was not affected by treatment with Ver(B) LLC tumor growth treated with an interrupted treatment schedule (n = 5–10 m
(C) A549 cells were injected into Rag2 null mice. At 2 weeks postinoculation, tre
images of lung capacity after 14 weeks of treatment. Red signal represents air volu
capacity for the same groups of mice (bottom) (n = 10–12 mice per group).
(D) Measurement of the number of experimental A549 metastases after treatment
frommice treated with placebo, Gem75 alone, or ldCil/Ver/Gem75. The bar chart s
treatment group).
(E) Tumor blood vessel density wasmeasured by counting the total number of bloo
tumors (n = 8–11 tumors analyzed per group).
(F) Tumor blood vessel perfusion. Representative images of PE-PECAM perfused
per group).
(G) Mean tumor blood vessel diameter (n = 5 tumors analyzed per group).
(H) Mean percentage of aSMA-negative blood vessels (n = 3–5 tumors analyzed
(I) Blood vessel density in tumor-free skin (n = 5 samples per group). Black and wh
(C) represent 5 mm, (D) 500 mm, (F) 25 mm.
Results are given as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.0001. (A–C) Tw
Calone, decreased significantly by treatment with Gem200 and to
a lesser extent by treatment with Gem75, reduced by treatment
with Ver/Gem75 to tumor sizes measured after Gem200 treat-
ment, and enhanced significantly by treatment with ldCil alone
(Reynolds et al., 2009). Using combinations of these drugs,
ldCil/Ver also enhanced tumor growth similar to those found
with ldCil alone. Surprisingly, ldCil/Gem75 treatment reduced tu-
mor size to lower than found in Gem200-treated mice, suggesting
that ldCil can enhance the efficacy of Gem, even at lower doses.
Overall, the triple combination of ldCil/Ver/Gem75 was the most
effective therapy tested (Figure 1A). Furthermore, using a cyc-
lical treatment schedule (three cycles of 1 week on and 1 week
off), mimicking human dosing regimens, administration of ldCil/
Ver/Gem75 combination inhibited tumor growth significantly
when compared with Gem75 alone (Figure 1B). Similar effects
were observed when replacing Gem with Cisplatin, indicating
that combining ldCil/Ver with another chemotherapeutic can
reduce LLC tumor growth (Figure S1A available online).
To test whether ldCil/Ver/Gem75 was also effective in a human
lung cancer model, Rag2 null immunodeficient mice were in-
jected via the tail vein with human lung cancer cells (A549). At
2 weeks after tumor cell injection, mice were then treated with
placebo, Gem75, or a combination of ldCil/Ver/Gem75. High-res-
olution microCT imaging showed that Gem75 treatment had no
apparent benefit over placebo-treated mice in controlling the
growth of A549 tumors. In contrast, treatment with ldCil/Ver/
Gem75 inhibited tumor burden significantly, giving lung capacity
readings similar to those in mice without tumors and minimizing
the percentage loss of lung capacity (Figure 1C). These effects
were sustained beyond cessation of treatment (Figure 1C).
Importantly, in this experimental metastasis model, the number
of A549 metastatic nodules was decreased significantly when
compared with placebo and Gem75-treated groups (Figure 1D).
Together, these results show that treatment with ldCil/Ver/
Gem75 is sufficient to inhibit the growth of human as well as mu-
rine lung cancers.
Analysis of lung tumor vasculature showed that any treatment
including ldCil enhanced tumor blood vessel density and perfu-
sion significantly, but Ver treatment did not (Figures 1E and
1F). In addition, treatment with ldCil/Ver and Cisplatin also
showed an increase in blood vessel density (Figure S1B). How-
ever, in contrast to Ver treatment, ldCil treatment had no sig-
nificant effect on blood vessel diameter (Figure 1G). Also, aice per group).
atment commenced. Shown here are representative high-resolution microCT
me in lungs. (Graphs) Lung capacity over time (top) and percentage loss of lung
. Representative images of hematoxylin and eosin (H&E)-stained lung sections
hows mean of number of experimental metastases per mouse (n = 10 mice per
d vessels across entire midline tumor sections for size-matched, age-matched
tumor blood vessels with endomucin immunostaining (n = 3 tumors analyzed
per group).
ite bars indicate treatment schedule (black is on, and white is off). Scale bars in
o-way ANOVA test. (D–I) Student’s t test. See also Figure S1.
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Figure 2. ldCil Plus Ver Treatment Increases Delivery to Tumors and Decreases Hypoxia
At 7 days postinoculation, LLC tumor-burdened mice were treated with either Gem75 alone or ldCil, Ver plus Gem75.
(A) Doppler ultrasonography indicates relative blood flow, tumor perfusion, and tumor blood volume. (Upper panels) Representative ultrasound images. (Lower
panels) Quantitation in both the tumor core and across the whole tumor (n = 4–5 tumors analyzed per group).
(B) HPLC-MS analysis of tumoral Gem (after both intravenous and i.p. injections) (n = 5 tumors per group).
(C) HPLC-MS analysis of Gem concentration in kidneys and livers from mice treated with ldCil/Ver or placebo alone (n = 9–10 kidneys or livers per group).
(D) Vascular leakage of Hoechst dye into tumors. Representative images Hoechst dye (blue) and PE-PECAM antibody (red). The graph shows relative
Hoechst:PE-PECAM levels (n = 4–5 tumors analyzed per group).
(E) Immunostaining of LLC tumor sections for hypoxia markers Glut1 and CAIX (n = 4–5 tumors analyzed per group). Scale bars in (A) represent 2 mm, (D) 25 mm,
and (E) 50 mm.
Results are given as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.0001. nsd, no significant difference. Student’s t test. See also Figure S2.
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Cancer Cell
Enhancing Chemotherapy Delivery and Efficacysignificant increase in the percentage of tumor blood vessels
that lack supporting a smooth muscle actin (aSMA)-positive
pericytes was observed in ldCil-treated mice, suggesting that
ldCil reduces tumor blood vessel stabilization (Figure 1H).
Changes in blood vessel density were not apparent in non-tu-
mor-burdened skin treated with either Gem75 or ldCil/Ver/
Gem75 (Figure 1I), suggesting that the proangiogenic effect is tu-
mor specific. These data demonstrate that the proangiogenic
and provascular effects of ldCil and Ver, respectively, are
apparent in vivo and correspond with improved Gem efficacy.
ldCil and Ver Increase Tumor Vascular Function and
Intratumoral Drug Delivery while Reducing Hypoxia
We next sought to investigate whether the increases in blood
vessel density, dilation, and perfusion together with loss of peri-
cyte coverage were sufficient to increase Gem delivery. Doppler
ultrasound analysis of microbubble perfusion revealed that LLC
tumor blood flow, perfusion, and total blood volume were all
increased significantly in mice treated with ldCil/Ver/Gem75
when comparedwithGem75 alone. The increase in thesedynamic
flow readouts was evident across the whole tumor, including the
tumor core (Figure 2A). We also show that reducing the Ver dose
10-fold in combination with ldCil/Gem75 is sufficient to signifi-
cantly reduce efflux regulation, but still enhance tumor blood
vessel diameter, blood flow, tumor perfusion, total blood volume,
while still controlling LLC tumor growth similar to that found for the
standard Ver doses used in our experiments (Figures S2A–S2D).
Moreover, high-performance liquid chromatography-mass spec-
trometry (HPLC-MS) analysis of intratumoral Gem, after either
intravenous or intraperitoneal Gem injection, was increased
significantly inmice treatedwith ldCil/Ver/Gem75when compared
with Gem75 alone (Figure 2B). Strikingly, ldCil/Ver/Gem75 treat-
ment did not increase Gem concentration in kidneys and livers
when compared with Gem75 alone (Figure 2C), indicating a level
of tumor specificity with this approach. Our data suggest that
treatment with ldCil/Ver/Gem75 results in a functional increase
in tumor vasculature and not simply an increase in numbers of
tumor blood vessels. Mice injected intravenously with Hoechst
dye showed a significant increase in intratumoral Hoechst dye
levels, relative to blood vessel levels, after treatment with ldCil
alone, Ver alone, and with a combination of ldCil/Ver when
compared with placebo-treated mice (Figure 2D). The increased
vessel leakage correlated with reduced platelet endothelial cell
adhesion molecule (PECAM) expression in tumor blood vessels
after treatmentwith ldCil alonewhen comparedwith placebo (Fig-
ure S2E). These data indicate increased vascular leakage and
improved tumor delivery with ldCil/Ver treatment.Figure 3. Combination Therapy Using ldCil, Ver, and Gem Significantly
In intervention trials, the effect of ldCil/Ver/Gem75 was tested in both an orthotop
(A) Tumor-burden mice bearing orthotopic DT6066 tumors. Quantitation of tumo
group).
(B) Blood vessel density in DT6066 tumors. Quantitation of blood vessel density
(n = 7 tumors analyzed per group).
(C) Spontaneous pancreatic tumor size in KPC mice. Representative images of e
(D) Blood vessel density in KPC pancreatic tumors. Representative images of en
(E and F) Desmoplastic reaction in DT6066 tumor-bearing mice and KPC mice af
H&E, Picrosirius Red (collagen), and aSMA (myofibroblast)-stained tumor section
Scale bars in (A) and (C) represent 1 cm, (E) (left panel) 50 mm, (F) (left panel) 10
means ± SEM. **p < 0.01, ***p < 0.0001. (A, B, and D–F) Student’s t test. (C) Two
128 Cancer Cell 27, 123–137, January 12, 2015 ª2015 Elsevier Inc.Tumor hypoxia is indicative of poor prognosis (Seigneuric
et al., 2007). By using two separate methods for hypoxia mea-
surement, histochemical analysis of glucose transporter 1
(Glut1) and carbonic anhydrase IX (CAIX), we show that ldCil,
Ver, or ldCil/Ver treatment can reduce tumor hypoxia signifi-
cantly (Figure 2E). Together, these data indicate that treatment
with ldCil/Ver can increase blood flow, perfusion, and vessel
permeability, leading to enhanced intratumoral drug delivery,
while reducing tumor hypoxia.
Combination ldCil and Ver Enhance the Efficacy of Gem
in the Treatment of Pancreatic Cancer
The effect of ldCil/Ver/Gem75 treatment was also tested on
pancreatic cancer, which is notoriously poorly vascularized
and currently treated with Gem monotherapy. KrasLSL-G12D/+;
p53R172H/+;Pdx1-Cre (KPC) mice harbor heterozygous condi-
tional mutant alleles ofKras and p53 as well as a pancreatic-spe-
cific Cre recombinase, Pdx1-Cre, and develop de novo PDAC
(Hingorani et al., 2005). DT6066 cells aremouse-derived pancre-
atic cancer cells. We tested the effect of ldCil/Ver/Gem75 on both
orthotopically injected DT6066 and spontaneous KPC pancre-
atic tumor growth. Orthotopic injection of DT6066 cells gener-
ated palpable pancreatic tumors within 14 days postinjection.
DT6066 tumor-bearing mice were given cyclical treatment
schedules of placebo, Gem75, or ldCil/Ver/Gem75. Gem75 treat-
ment was not sufficient to affect endpoint tumor size (2 months
after tumor cell inoculation), while mice treated with ldCil/Ver/
Gem75 developed significantly smaller tumors (Figure 3A). Treat-
ment with ldCil/Ver/Gem75 was also sufficient to increase
DT6066 tumor blood vessel density significantly (Figure 3B).
Reminiscent of our previous findings in LLC tumors (Reynolds
et al., 2009), treatment including ldCil induced an increase in
vascular endothelial growth factor (VEGF) receptor 2 expression
in DT6066 pancreatic cancer in vivo (Figure S3A).
Similar to our results with DT6066 tumors, Gem75 treatment
showed no apparent effect on spontaneous pancreatic tumor
growth in KPC mice when compared with placebo. However,
ldCil/Ver/Gem75 reduced significantly the growth of pancreatic
tumors, and this effect persisted after treatment cessation (Fig-
ure 3C). Treatment with the maximally tolerated dose of Gem
(125 mg/kg) with ldCil/Ver also reduced tumor growth signifi-
cantly in KPC mice (Figure S3B). Pancreatic tumor blood vessel
density was increased in ldCil/Ver/Gem75 treated KPCmice (Fig-
ure 3D). Tumor desmoplasia, one of the salient features of
pancreatic cancer, contributes to pancreatic tumor progression
and chemoresistance (Erkan et al., 2012; Hwang et al., 2008). Tu-
mor desmoplasia is characterized by enhanced aSMA-positiveReduces Pancreatic Tumor Growth and Desmoplasia
ic (DT6066) and spontaneous (KPC) model of pancreatic cancer.
r size and images of representative endpoint tumors are given (n = 8 mice per
and representative images of endomucin-stained DT6066 sections are given
ndpoint pancreatic KPC tumors are given (n = 7–10 mice per group).
domucin-stained sections (n = 7–10 mice per group).
ter treatment (n = 10–15 mice per group). Representative images are shown of
s. Black and white bars indicate treatment schedule (black on and white off).
0 mm, and (B) and (D–F) (middle and right panels) 25 mm. Results are given as
-way ANOVA test. See also Figure S3.
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Figure 4. Combination Therapy Using ldCil, Ver, and Gem Significantly Reduces Tumor Hypoxia and Metastasis
(A and B) Tumor hypoxia was tested by staining tumor sections frommice bearing orthotopic DT6066 tumors or KPCmice treated with placebo, Gem75, or ldCil/
Ver/Gem75 for both Glut1 and carbonic anhydrase (CAIX) (n = 5–9 tumors analyzed per group). Representative images are given. Graphs represent hypoxia levels.
(C) Pancreatic cancer progression, in treated KPC mice, was measured by counting the percentage of ducts at different stages in intraepithelial neoplasias and
the percentage of invasive areas in PDAC (n = 7–10 mice per group).
(D) The percentage of pancreatic cancer necrotic areas in treated KPC mice (n = 7–10 mice per treatment group).
(legend continued on next page)
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Enhancing Chemotherapy Delivery and Efficacymyofibroblast infiltration and collagen deposition. Immunostain-
ing showed reduced desmoplasia in orthotopically grown tu-
mors, pancreatic tumors from KPC mice, and LLC tumors
treated with ldCil/Ver/Gem75 (Figures 3E, 3F, and S3C). A reduc-
tion in tumor desmoplasia has been shown to be linked to in-
hibited sonic hedgehog signaling and subsequently reduced
downstream Gli1 expression (Olive et al., 2009). Corroborating
the reduced desmoplasia observed in ldCil/Ver/Gem75-treated
KPC mice, Gli1 expression was also reduced (Figure S3D).
Another characteristic of pancreatic cancer is increased tu-
mor hypoxia, which is associated with chemoresistance and en-
hanced metastasis. We show that tumor hypoxia, measured by
Glut1 and CAIX immunodetection in DT6066 and KPC pancre-
atic tumor sections, was reduced significantly in mice treated
with ldCil/Ver/Gem75 (Figures 4A and 4B). Pancreatic cancer
progresses through morphologically distinct grades (PanIN-1,
PanIN-2, PanIN-3) up to PDAC. We show that treatment of
KPC mice with ldCil/Ver/Gem75 reduced disease progression,
resulting in a lower proportion of high-grade tumors (Figure 4C).
Blood vessel density was increased by treatment, including
ldCil, in both low- and high-grade regions of pancreatic tumors
(Figure S4A). An increase in tumor necrosis, and correlating
cellular apoptosis, was also observed in ldCil/Ver/Gem75-
treated mice (Figures 4D and S4B). Previous reports have shown
that hypoxia is associated with metastasis (Eisinger-Mathason
et al., 2013; Yang et al., 2008). Our results show that KPC
mice treated with ldCil/Ver/Gem75 have significantly lower
numbers and frequency of metastases (Figures 4E and 4F).
Overall, treatment with ldCil/Ver/Gem75 extended survival
significantly (Figure 4G). Together, these data demonstrate
that ldCil/Ver/Gem75 is an effective method to control pancreatic
cancer growth and spread above and beyond treatment with
Gem75 alone.
ldCil Elevates Gem Uptake and Metabolism
Since treatment with ldCil increases Gem efficacy, we tested the
effect of ldCil on the expression of the Gem transporters equili-
brative nucleoside transporters 1 and 2 (ENT1 and ENT2) and
concentrative nucleoside transporter 3 (CNT3), its rate-limiting
metabolizing enzyme deoxycytidine kinase (DCK) and catabo-
lizing enzyme cytidine deaminase (CDA). Previous work has es-
tablished that hypoxia can regulate ENT1 and ENT2 expression
in vivo (Eltzschig et al., 2005; Morote-Garcia et al., 2009). In line
with this, immunohistochemical analysis revealed that treatment
of LLC tumor-bearing mice with therapies containing ldCil, i.e.,
where tumor angiogenesis, leakage, and blood flow are en-
hanced, while hypoxia is reduced, is sufficient to increase
ENT1 and ENT2 expression levels. A similar pattern of expres-
sion was observed for CNT3. Since the cytotoxic efficacy of
Gem depends on its phosphorylation by DCK (Plunkett et al.,
1995), we next examined the expression of DCK in LLC tumor
sections. Immunohistochemical analysis showed an increase
in DCK expression levels in LLC tumor sections from mice(E) The number of pancreatic metastases in KPC mice after treatment (n = 14–15
(F) The incidence of pancreatic metastasis in treated KPC mice (n = 14–15 mice
(G) Survival of treated KPC mice (n = 14–18 mice per treatment group). Scale ba
Results are given as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.0001. nsd, no
(Mantel-Cox) test. See also Figure S4.
130 Cancer Cell 27, 123–137, January 12, 2015 ª2015 Elsevier Inc.treated with ldCil corresponding with transporter levels (Fig-
ure 5A). In line with these observations, CDA levels were reduced
after all treatments but most significantly after treatment with
ldCil/Ver/Gem75 (Figure 5A). Indeed, increased expression of
ENT1, ENT2, CNT3, and DCK together with reduced levels of
CDA was also observed in pancreatic tumors from KPC mice
that had been treated with ldCil/Ver/Gem75 (Figure 5B). Similar
results for ENT1, DCK, and CDA staining were observed in
pancreatic tumors isolated from ldCil/Ver/Gem125-treated mice
(Figure S5A). The negative regulation of internalized Gem is gov-
erned further by ribonucleotide reductase M1 (RRM1). Immu-
nohistochemical analysis of KPC pancreatic tumor sections
showed that RRM1 levels were decreased after treatment with
ldCil/Gem75 but not Gem75 alone (Figure S5B). These data link
the vascular promotion feature of ldCil/Ver treatment with
increased Gem uptake and metabolism and resulting efficacy
in vivo.
ldCil Increases Intracellular Gem Levels In Vitro
The enhanced efficacy of Gem75, when used in combination with
ldCil and/or Ver, is likely due to a combination of the increased
intratumoral delivery of this chemotherapeutic together with
increased oxygenation that improves chemosensitivity. How-
ever, it is possible that ldCil and Ver may also have a direct effect
on drug uptake into tumor cells, independent of angiogenesis
and blood flow. Previous work has shown that Ver can inhibit
P-glycoprotein activity, an important regulator of Gem efflux
(Bergman et al., 2003). In contrast, we show that treatment
with ldCil had no effect on p-glycoprotein activity in cultured
LLC, A549, or DT6066 cells (Figure S6A). However, using
HPLC-MS analysis, we confirm that intracellular Gem (dFdC)
and its active metabolite (dFdCTP) are both increased in LLC
cells after treatment with Ver in vitro, and surprisingly, treatment
with ldCil also increased the intracellular levels of dFdC and
dFdCTP significantly in cultured LLC cells; ldCil/Ver enhanced
these even further (Figure 6A). Importantly, ldCil/Ver/Gem75
treatment induced a higher concentration of intracellular Gem
in tumor cells than treatment with higher doses of Gem (i.e.,
150 nM, Gem150) alone (Figure S6B), suggesting that ldCil/Ver
can improve the efficacy of Gem even at lower doses. Moreover,
although ldCil had no effect on altering cultured endothelial cell
sensitivity to Gem, it reduced significantly the relative survival
of Gem-treated LLC, A549, and DT6066 cells (Figure 6B). As ex-
pected, Ver enhanced the cytotoxic effect of Gem in LLC, A549
and DT6066 cells, but not endothelial cells in 3-(4,5-dimethylth-
iazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) (MTS) cell viability assays in vitro (Figure S6C). This
in vitro effect was not reproduced when replacing Gem with
Cisplatin (Figure S6D). Western blot analysis revealed that
CNT3 and DCK levels were increased, while CDA and RRM1
levels were decreased significantly in Gem-stimulated, cultured
LLC, A549, and DT6066 cells treated with ldCil/Gem75, but not
Gem75 alone (Figure 6C). In contrast, treatment of endothelialmice per treatment group). Representative H&E images of liver metastases.
per treatment group).
r in (A and B) represent 50 mm and (E) 5 mm.
significant difference. (A–E) Student’s t test. (F) Chi-square test. (G) Log-rank
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CNT3, DCK, CDA, or RRM1 (Figure S6E). Together, these data
suggest that ldCil affects Gem uptake and metabolism via
altering CNT3, DCK, and CDA levels in tumor cells.
Our results indicate a feature of ldCil as an enhancer of intra-
cellular Gem concentration and cytotoxic effects distinct from
the effects of Ver. We next sought to examine the molecular
regulation of this increased intracellular Gem concentration by
ldCil. Transporter regulator 1 (RS1) is known to control CNT3
activity (Errasti-Murugarren et al., 2012) while Cilengitide was
raised to have specificity for both b3- and b5-integrin subunits
(Mas-Moruno et al., 2010). Although ldCil has no direct effect
on b3- or b5-integrin subunit expression levels, RS1 levels
were increased after ldCil/Gem75 treatment in tumor cells (Fig-
ure 6D), and siRNA depletion of b5-integrin, but not b3-integrin,
subunit was sufficient to decrease RS1 levels (Figure 6E). These
results suggest that the b5-integrin subunit could regulate RS1
and possibly control Gem sensitivity in tumor cells. Indeed, this
was confirmed in MTS cell survival assays where siRNA deple-
tion of b5-integrin, but not b3-integrin, subunits was sufficient to
partially rescue cell survival after ldCil/Gem75 treatment (Fig-
ure 6F). Furthermore, a direct role for CNT3 in ldCil sensitivity
was also demonstrated. MTS cell survival assays were per-
formed by pharmacological inhibition of CNT3 using Phloridzin
(Errasti-Murugarren et al., 2007). Inhibition of CNT3 had no ef-
fect on ldCil-treated cell survival in the absence of Gem75. In
contrast, Phloridzin treatment rescued cell survival after treat-
ment with ldCil/Gem75 (Figure 6G). Together, the results indicate
that ldCil, via regulation of b5-integrin subunit, RS1, and CNT3
can regulate sensitivity to Gem and thus control tumor cell
survival.
Minimizing Adverse Side Effects
An important aspect of improved cancer therapy is to minimize
side effects. Gem, administered at 200 mg/kg in mice, is equiv-
alent to a low dose of Gem used clinically (600–1,200 mg/m2).
Common adverse effects of Gem include nausea and vomiting,
anemia, increased liver enzyme levels (ALT, AST), neutropenia,
leukopenia, thrombocytopenia, and others. Our results show
that administration of Gem200 has serious deleterious effects in
mice and is associated with significant weight loss in mice over
a period of 4–5 weeks. In contrast, administration of ldCil/Ver/
Gem75 has minimal apparent effect on body weight (Figure 7A).
Hematological analysis showed that administration of Gem200
reduced white blood cell, neutrophil, red blood cell, hemoglobin,
and platelet counts significantly, while administration of ldCil/
Ver/Gem75 minimized these effects (Figure 7B). In addition, liver
toxicity, measured by levels of ALT and AST, was in normal
ranges after administration of ldCil/Ver/Gem75 but increased
significantly after treatment with Gem200 (Figure 7C). These re-
sults suggest that ldCil/Ver/Gem75 is an effective treatment
regime with reduced side effects.Figure 5. ldCil Enhances Gem Metabolism
(A) Immunohistochemical analysis of ENT1 and ENT2, CNT3, DCK, and CDA i
combinations of these treatments. Representative images are given (n = 6–8 tum
(B) Immunohistochemical analysis of ENT1, ENT2, CNT3, DCK, and CDA in pancr
Representative images are given (n = 6–8 tumors analyzed per group). Scale bar
Bar charts represent mean staining scores ± SEM. *p < 0.05, **p < 0.001, ***p <
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Our results demonstrate that vascular promotion, by increasing
tumor blood vessel density, blood flow, leakiness, and dilation,
increases chemotherapy delivery and intracellular uptake of
the drug and reduces hypoxia. Together, this leads to reduced
cancer growth and metastasis. These results are unexpected
and call for consideration of vascular promotion strategies in
combination with chemotherapy for the treatment of cancer.
Elevated blood vessel numbers and increased vascular
leakage have been shown to promote both tumor growth and
cancer metastasis (Weidner et al., 1991). Although promising re-
sults have been achieved preclinically, improvements to current
antiangiogenic therapies are still ongoing (Shojaei, 2012). For
example, some data suggest that antiangiogenic therapy can
increase intratumoral hypoxia, leading to radioresistance and
chemoresistance as well as potentially increasing metastasis,
at least in mouse models (Ebos et al., 2009; Pa`ez-Ribes et al.,
2009). Additionally, reducing angiogenesis can impair drug deliv-
ery to the tumor, ultimately restricting its efficacy (Van der Veldt
et al., 2012). Vascular normalization, using antiangiogenic
agents, is the process by which partial loss of blood vessel den-
sity is associated with a temporary increase in blood flow (Car-
meliet and Jain, 2011). This approach has shown significant
promise (Batchelor et al., 2007; Huang et al., 2012), but since it
relies on a temporal window of opportunity that is both time
and dose dependent and may well be different for different can-
cer types, it is generally considered difficult to implement clini-
cally (Webb, 2005). Thus, alternative strategies that overcome
these issues are needed.
In contrast, our data point toward a possible radical change
in therapeutic strategy by vascular promotion. Using a proangio-
genic, low dose of Cilengitide and Ver in combination with Gem,
we show that this strategy can actually improve cancer therapy
and allows for lower doses of Gem to work more effectively
than higher doses. How do we explain our findings?
First, previous studies using Ver for cancer therapy showed
that although tumor perfusion was improved, this effect was
transient and showed no overall benefit (Wood and Hirst,
1989). Clinically, Ver was used at high doses where it caused
adverse effects such as hypotension (Miller et al., 1991). Newer
evidence suggests that lowering the Ver dose can provide
benefit and reduce side effects (Ahmed et al., 1992; Feng
et al., 2002). In our experiments, Ver was used at low doses (Can-
dussio et al., 2002), and in contrast to previous vascular modu-
lation strategies, our data demonstrate that combining ldCil
and Ver increases tumor blood vessel density, tumor blood
flow, tumor blood volume, and tumor perfusion and enhances
chemotherapeutic delivery. These are important features of the
vascular promotion approach given here. This delays cancer
progression significantly, even after the cessation of treatment.
Importantly, the benefits of this vascular promotion strategyn LLC tumor sections from mice treated with placebo, ldCil, Ver, Gem75, or
ors analyzed per group).
eatic tumors from KPC mice treated with placebo, Gem75, or ldCil/Ver/Gem75.
s in (A) and (B) represent 50 mm.
0.0001. Student’s t test. See also Figure S5.
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Enhancing Chemotherapy Delivery and Efficacyappears to be relevant to cancer types that are both highly vas-
cularized and also poorly vascularized tumors, suggesting a
broad range of efficacy.
Second, vascular promotion is associated with reduced tumor
hypoxia, desmoplasia, andmetastasis. Current evidence reveals
that enhanced tumor hypoxia directly accelerates desmoplasia
(Spivak-Kroizman et al., 2013). Our data corroborate these find-
ings. We show that reduced hypoxia, after vascular promotion
treatment, is associated with a significant reduction in desmo-
plastic reaction—a salient feature of PDAC. Our data indicate
that ldCil/Ver/Gem75 decreased the number of tumor-associ-
ated, aSMA-positive myofibroblasts and collagen levels, typical
of an inhibited desmoplastic reaction. Although the concept that
increased desmoplasia impairs drug delivery is somewhat
controversial (Olive et al., 2009; O¨zdemir et al., 2014; Proven-
zano et al., 2012; Rhim et al., 2014), it is tempting to suggest
that the reduced desmoplastic reaction observed after vascular
promotion contributes to improved Gem delivery. Increased
hypoxia has also been shown to promote epithelial-mesen-
chymal transition (EMT), leading to chemoresistance andmetas-
tasis (Yokoi and Fidler, 2004). The decrease in the number and
incidence of liver metastases that we observed in pancreatic
tumor models after treatment with ldCil/Ver/Gem75 may there-
fore be attributed to the inhibition of EMT via the reduction of
hypoxia.
Finally, our data describe a feature of ldCil as a regulator of
Gem uptake and metabolism in tumor cells. ENT1 and ENT2
regulate Gem uptake, and ENT1 has been reported to predict re-
sponses to this chemotherapeutic in pancreatic cancer (Farrell
et al., 2009). Our data demonstrate clearly that vascular promo-
tion is associated with a significant upregulation of ENT1 and
ENT2 in less hypoxic pancreatic and lung tumors. These findings
are supported by other studies identifying hypoxia-inducible fac-
tor 1-a as a transcriptional repressor of ENT1 and ENT2 (Eltz-
schig et al., 2005; Morote-Garcia et al., 2009). ENTs catalyze a
passive diffusion process both into and out of the cell depending
on the concentration gradient of Gem. Therefore, we have addi-
tionally focused on CNT3, whichmediates the unidirectional flow
of the drug into the cell by an active process (Young et al., 2013).
CNT3 is upregulated significantly after treatment containing ldCil
in vitro and in vivo. At a mechanistic level, we show that treat-
ment with ldCil does not affect the expression levels of b3- or
b5-integrin subunits, but does upregulate the expression of a
positive regulator of CNT3, namely, transporter regulator 1
(RS1) (Errasti-Murugarren et al., 2012). Interestingly, depletion
of b5-intergrin, but not b3-integrin subunit, is sufficient to reduceFigure 6. ldCil Enhances the Efficacy of Gem on Cultured Tumor Cells
(A) HPLC-MS analysis of Gem dFdC and dFdCTP levels of treated LLC cells in v
(B) MTS cell survival assays of endothelial cells, LLC, A549, and DT6066 tumor ce
(C) Western blot analysis for CNT3, DCK, CDA, RRM1, and loading control HSC7
repeats).
(D) Western blot analysis of b3- and b5-integrin subunits and RS1 in LLC and DT6
repeats). Bar charts represent mean densitometric values normalized to Gem75 c
(E) siRNA depletion of b3- or b5-integrin subunits followed by western blot anal
experimental repeats). Bar charts represent mean ± SEM densitometric values n
(F)MTS cell survival assays, after siRNA targeting of b5- and b3-integrin subunits, c
are means ± SEM relative to scr siRNA controls treated with ldCil alone.
(G)MTS cell survival data of LLC andDT6066 tumor cells incubated with CNT3 inhi
Results are given as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.0001. nsd, no
134 Cancer Cell 27, 123–137, January 12, 2015 ª2015 Elsevier Inc.RS1 levels and similar to the effect of pharmacological inhibition
of CNT3 with phloridzin rescues cell survival in the presence of
ldCil/Gem75. These results indicate one possible mechanism
by which ldCil can regulate tumor cell sensitivity to Gem and
other related chemotherapeutics that require CNT3 activity.
Moreover, we show that ldCil can additionally regulate Gem-
metabolizing enzymes in vitro and in vivo. Recent pharmacolog-
ical studies have revealed that DCK activity can be saturated at
relatively lower plasma concentrations of Gem, while greater
doses are required to saturate CDA (Gusella et al., 2011). Here
we propose that the increase in Gem uptake, combined with
the decreased efflux of the drug, leads to the enhanced expres-
sion and saturation of DCK, producing higher amounts of the
active Gem metabolite. Many attempts are presently underway
to improve the tumor specific effects of Gem (Olive et al.,
2009). Our data indicate an alternative method to improve Gem
efficacy.
The broader application of using ldCil/Ver to improve chemo-
therapy depends on its ability to enhance the efficacy of other
cancer therapies. We have evidence that Cisplatin efficacy is
improved in combination with ldCil/Ver in vivo. This corresponds
with an increase in blood vessel density. Interestingly, and in
contrast to combination treatment with Gem, Cisplatin efficacy
is not enhanced by ldCil or Ver in vitro. This suggests that ldCil
does not affect the transporters of Cisplatin. These data provide
an example of how the vascular promotion effects of ldCil/Ver
can enhance chemotherapy outcome independent of a direct
effect on the tumor cell killing. Thus, we can speculate that the
efficacy of some chemotherapeutics may benefit from combina-
tion with ldCil/Ver by a dual action on increasing delivery and
increasing tumor killing. For others, it may be sufficient to only
improve delivery to affect tumor growth.
Reducing side effects is an important feature of improving
cancer treatment. Here we propose that vascular promotion al-
lows significantly reduced doses of Gem to be used effectively.
By enhancing intratumoral delivery and intracellular uptake of the
cytotoxic drug, we are able to minimize adverse effects of the
therapy, while enhancing its efficacy. Thus, this strategy could
provide the opportunity to extend treatment duration without
reducing quality of life.
Overall, our data provide proof of principle that vascular pro-
motion can improve the efficacy of cancer treatment. This strat-
egy may be particularly relevant to other neoplasms with low
blood vessel density, including metastases. In the future, under-
standing the potential relevance of vascular promotion to other
nucleoside analogs, different classes of chemotherapeutics,Independent of Angiogenesis
itro (n = 3–4 experimental repeats).
lls after treatment with Gem plus or minus ldCil (n = 3–4 experimental repeats).
0 after treatment with either Gem75 or ldCil/Gem75 in vitro (n = 3 experimental
066 cells treated with either Gem75 or ldCil/Gem75 in vitro (n = 3 experimental
ontrols ± SEM.
ysis of b3-integrin, b5-integrin, and RS1 levels. HSC70, loading control (n = 3
ormalized to scr (scrambled) siRNA controls.
ombinedwithGem75 and ldCil treatment (n = 4–6 experimental repeat). Results
bitor, phloridzin plus ldCil with or without Gem75 (n = 3–5 experimental repeats).
significant difference. Student’s t test. See also Figure S6.
AB
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Figure 7. Minimizing Adverse Side Effects Using ldCil/Ver/Gem75
C57/BL6 mice are treated with placebo, Gem200, or ldCil/Ver/Gem75.
(A) Mouse body weights.
(B) Hematological analysis of white blood cells, neutrophils, red blood cells, hemoglobin, and platelets in blood plasma.
(C) Biochemical analysis of liver damage response enzymes ALT and AST (n = 5–10 mice per treatment group).
Results are given as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.0001. Student’s t test.
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Enhancing Chemotherapy Delivery and Efficacybiological therapies, or radiotherapy is warranted. Our data open
up a field of research where exploiting vascular promotion may
be an effective method to improve cancer treatment.
EXPERIMENTAL PROCEDURES
Treatments
Gem (38 mg/ml, Hospria) and Ver (40 mg/5 ml Zolvera, Rosemant) were pur-
chased from Barts Hospital’s pharmacy and used within 3 months. Cilengitide
was purchased from Bachem. The dose of Cilengitide used in this paper was
obtained from previous publication (Reynolds et al., 2009).
Continuous Treatment
Mice were administered with the following either alone or in combination:
50 mg/kg Cilengitide (ldCil) by intraperitoneal (i.p.) injection three times a
week and/or 5 mg/kg/day Ver continuously in drinking water and/or Gem75
or Gem125 or Gem200 by i.p. injection three times a week.
Interrupted Treatment
Mice were administered ldCil, Ver, and Gem as above but in cycles, 1 week on
and 1 week off, for as many cycles as indicated in the figures.
Subcutaneous and Experimental Metastasis Models
C57/BL6 (Charles River) micewere given a subcutaneous injection of 0.53 106
LLC cells into the flank for subcutaneous tumor growth. Tumor growth was
measured by using calipers every 2 days. Tumor volume (V) was calculated:
V = (length3 width2)3 0.52. For experimental metastasis assays, 23 106 hu-
man non-small-cell lung cancer cells (A549) were injected via the tail vein of
Rag2 null immunodeficient mice. At 14 days postinoculation, the mice were
given three interrupted cycles of treatment, and tumor burden was measured
by microCT (see Supplemental Experimental Procedures).
Surgical Orthotopic Pancreatic Cancer Mouse Model
Male C57/129micewere implantedwithmouse-derived pancreatic cancer cell
line (DT6066) into the pancreas, 1 3 106 DT6006 cells in 40 ml PBS.
Spontaneous Pancreatic Cancer Model: KPC
KPC mice (KrasLSLG12D/+;p53R172H/+;Pdx1-Cre) (Hingorani et al., 2005) were
enrolled randomly when pancreatic cancers reached 5–10 mm diameter and
were scanned and quantified by 3D ultrasonography (see Supplemental
Experimental Procedures).
Ethical Regulations
All procedures were approved by our local animal ethics committee, Queen
Mary University of London, and were executed in accordance with United
Kingdom Home Office regulations.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.ccell.2014.10.015.
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